Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer
NCT ID: NCT00387764
Last Updated: 2014-01-14
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
80 participants
INTERVENTIONAL
2006-09-30
2012-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma
NCT00992121
Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma
NCT00720941
Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma
NCT01649778
Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma
NCT01147822
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
NCT01575548
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
pazopanib arm
This was a single arm study, therefore no control arm.
pazopanib
800 mg daily dosing continously until progression
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
pazopanib
800 mg daily dosing continously until progression
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient's VEG105192 was placebo
* Baseline has good organ function
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Capital Federal, Buenos Aires, Argentina
GSK Investigational Site
Córdoba, Córdoba Province, Argentina
GSK Investigational Site
Rosario, Santa Fe Province, Argentina
GSK Investigational Site
Quilmes, , Argentina
GSK Investigational Site
San Miguel de Tucumán, , Argentina
GSK Investigational Site
Waratah, New South Wales, Australia
GSK Investigational Site
Hobart, Tasmania, Australia
GSK Investigational Site
Heidelberg, Victoria, Australia
GSK Investigational Site
Salzburg, , Austria
GSK Investigational Site
Vienna, , Austria
GSK Investigational Site
Belo Horizonte, Minas Gerais, Brazil
GSK Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
GSK Investigational Site
Viña del Mar, Región de Valparaíso, Chile
GSK Investigational Site
Santiago, Región Metro de Santiago, Chile
GSK Investigational Site
Beijing, , China
GSK Investigational Site
Beijing, , China
GSK Investigational Site
Brno, , Czechia
GSK Investigational Site
Chomutov, , Czechia
GSK Investigational Site
Prague, , Czechia
GSK Investigational Site
Tartu, , Estonia
GSK Investigational Site
Rome, Lazio, Italy
GSK Investigational Site
Rome, Lazio, Italy
GSK Investigational Site
Riga, , Latvia
GSK Investigational Site
Kaunas, , Lithuania
GSK Investigational Site
Vilnius, , Lithuania
GSK Investigational Site
Christchurch, , New Zealand
GSK Investigational Site
Wellington, , New Zealand
GSK Investigational Site
Karachi, , Pakistan
GSK Investigational Site
Lahore, , Pakistan
GSK Investigational Site
Gdansk, , Poland
GSK Investigational Site
Krakow, , Poland
GSK Investigational Site
Krakow, , Poland
GSK Investigational Site
Olsztyn, , Poland
GSK Investigational Site
Olsztyn, , Poland
GSK Investigational Site
Chelyabinsk, , Russia
GSK Investigational Site
Kazan', , Russia
GSK Investigational Site
Moscow, , Russia
GSK Investigational Site
Moscow, , Russia
GSK Investigational Site
Moscow, , Russia
GSK Investigational Site
Omsk, , Russia
GSK Investigational Site
Saint Petersburg, , Russia
GSK Investigational Site
Samara, , Russia
GSK Investigational Site
Voronezh, , Russia
GSK Investigational Site
Yaroslavl, , Russia
GSK Investigational Site
Bratislava, , Slovakia
GSK Investigational Site
Seoul, , South Korea
GSK Investigational Site
Seoul, , South Korea
GSK Investigational Site
Songpa-gu, Seoul, , South Korea
GSK Investigational Site
Sfax, , Tunisia
GSK Investigational Site
Sousse, , Tunisia
GSK Investigational Site
Tunis, , Tunisia
GSK Investigational Site
Tunis, , Tunisia
GSK Investigational Site
Donetsk, , Ukraine
GSK Investigational Site
Kharkiv, , Ukraine
GSK Investigational Site
Kyiv, , Ukraine
GSK Investigational Site
Bebington, Wirral, , United Kingdom
GSK Investigational Site
Belfast, Northern Ireland, , United Kingdom
GSK Investigational Site
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VEG107769
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.